Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of KN056 in Healthy Participants
NCT05385575Phase 1Completed
- Sponsor
- Alphamab Oncology
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KN056 in type 2 diabetes mellitus (T2DM) (7 cohorts), sponsored by Alphamab Oncology. Primary endpoints: Treatment-Emergent Adverse Events up to 45 days, Severity of Treatment-Emergent Adverse Events up to 45 days and 3 more. Started Aug 2022; status: completed.
02
Drugs
KN056
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05385575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385575.